Recruitment of the tumour suppressor protein p73 by Kaposi's Sarcoma Herpesvirus latent nuclear antigen contributes to the survival of primary effusion lymphoma cells

Oncogene

Volumn 32, Issue 32, 2013, Pages 3676-3685

  Schulz, T F ^a   Santag, S ^a   Jager W ^a   Karsten, C B ^a   Kati, S ^a   Pietrek, M ^a   Steinemann, D ^a   Sarek, G ^b   Ojala, P M ^a,c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF HELSINKI   (Finland)

^c Foundation for the Finnish Cancer Institute   (Finland)

Author keywords

KSHV; LANA; Nutlin 3; p73; primary effusion lymphoma; RETRA

Indexed keywords

CELL NUCLEUS ANTIGEN; LATENCY ASSOCIATED NUCLEAR ANTIGEN 1; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; PROTEIN P73; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; KAPOSI SARCOMA; LYMPHOMA CELL; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION;

ANTIGENS, VIRAL; APOPTOSIS; BINDING SITES; CATECHOLS; CELL SURVIVAL; DNA DAMAGE; DNA-BINDING PROTEINS; HEK293 CELLS; HELA CELLS; HUMANS; IMIDAZOLES; LYMPHOMA, PRIMARY EFFUSION; NUCLEAR PROTEINS; PIPERAZINES; THIAZOLES; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

HERPESVIRIDAE; HUMAN HERPESVIRUS 8;

EID: 84881479749     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.385     Document Type: Article

References (56)

1. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865-1869.
2. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332: 1186-1191.
3. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995; 86: 1276-1280.
4. Wang L, Damania B. Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells. Cancer Res 2008; 68: 4640-4648.
5. Pan H, Zhou F, Gao SJ. Kaposi's sarcoma-associated herpesvirus induction of chromosome instability in primary human endothelial cells. Cancer Res 2004; 64: 4064-4068.
6. Kliche S, Kremmer E, Hammerschmidt W, Koszinowski U, Haas J. Persistent infection of Epstein-Barr virus-positive B lymphocytes by human herpesvirus 8. J Virol 1998; 72: 8143-8149.
7. Guasparri I, Keller SA, Cesarman EKSHV. vFLIP is essential for the survival of infected lymphoma cells. J Exp Med 2004; 199: 993-1003.
8. Godfrey A, Anderson J, Papanastasiou A, Takeuchi Y, Boshoff C. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood 2005; 105: 2510-2518.
9. Wies E, Mori Y, Hahn A, Kremmer E, Sturzl M, Fleckenstein B et al. The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells. Blood 2008; 111: 320-327.
10. Renne R, Barry C, Dittmer D, Compitello N, Brown PO, Ganem D. Modulation of cellular and viral gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol 2001; 75: 458-468.
11. An FQ, Compitello N, Horwitz E, Sramkoski M, Knudsen ES, Renne R. The latencyassociated nuclear antigen of Kaposi's sarcoma-associated herpesvirus modulates cellular gene expression and protects lymphoid cells from p16 INK4A-induced cell cycle arrest. J Biol Chem 2005; 280: 3862-3874.
12. Melino G, Lu X, Gasco M, Crook T, Knight RA. Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci 2003; 28: 663-670.
13. Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res 2004; 2: 371-386.
14. Grob TJ, Novak U, Maisse C, Barcaroli D, Luthi AU, Pirnia F et al. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 2001; 8: 1213-1223.
15. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857-860.
16. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-299.
17. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420: 25-27.
18. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299-303.
19. Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X et al. MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 1999; 19: 3257-3266.
20. Marin MC, Jost CA, Irwin MS, DeCaprio JA, Caput D, Kaelin Jr WG. Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol Cell Biol 1998; 18: 6316-6324.
21. Roth J, Konig C, Wienzek S, Weigel S, Ristea S, Dobbelstein M. Inactivation of p53 but not p73 by adenovirus type 5 E1B 55-kilodalton and E4 34-kilodalton oncoproteins. J Virol 1998; 72: 8510-8516.
22. Steegenga WT, Shvarts A, Riteco N, Bos JL, Jochemsen AG. Distinct regulation of p53 and p73 activity by adenovirus E1A, E1B, and E4orf6 proteins. Mol Cell Biol 1999; 19: 3885-3894.
23. Kaida A, Ariumi Y, Ueda Y, Lin JY, Hijikata M, Ikawa S et al. Functional impairment of p73 and p51, the p53-related proteins, by the human T-cell leukemia virus type 1 Tax oncoprotein. Oncogene 2000; 19: 827-830.
24. Park JS, Kim EJ, Lee JY, Sin HS, Namkoong SE, Um SJ. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins. Int J Cancer 2001; 91: 822-827.
25. Accardi R, Dong W, Smet A, Cui R, Hautefeuille A, Gabet AS et al. Skin human papillomavirus type 38 alters p53 functions by accumulation of deltaNp73. EMBO Rep 2006; 7: 334-340.
26. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
27. Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996; 88: 645-656.
28. Katano H, Sato Y, Sata T. Expression of p53 and human herpesvirus-8 (HHV-8)-encoded latency-associated nuclear antigen with inhibition of apoptosis in HHV-8-associated malignancies. Cancer 2001; 92: 3076-3084.
29. Friborg Jr J, Kong W, Hottiger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999; 402: 889-894.
30. Si H, Robertson ES. Kaposi's sarcoma-associated herpesvirus-encoded latencyassociated nuclear antigen induces chromosomal instability through inhibition of p53 function. J Virol 2006; 80: 697-709.
31. Cai QL, Knight JS, Verma SC, Zald P, Robertson ES. EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog 2006; 2: e116.
32. Petre CE, Sin SH, Dittmer DP. Functional p53 signaling in Kaposi's sarcomaassociated herpesvirus lymphomas: implications for therapy. J Virol 2007; 81: 1912-1922.
33. Sarek G, Kurki S, Enback J, Iotzova G, Haas J, Laakkonen P et al. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Invest 2007; 117: 1019-1028.
34. Chen W, Hilton IB, Staudt MR, Burd CE, Dittmer DP. Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma-associated Herpesvirus Lymphomas. J Virol 2010; 84: 3898-3908.
35. Santarelli R, Farina A, Granato M, Gonnella R, Raffa S, Leone L et al. Identification and characterization of the product encoded by ORF69 of Kaposi's sarcomaassociated herpesvirus. J Virol 2008; 82: 4562-4572.
36. Ohsaki E, Suzuki T, Karayama M, Ueda K. Accumulation of LANA at nuclear matrix fraction is important for Kaposi's sarcoma-associated herpesvirus replication in latency. Virus Res 2009; 139: 74-84.
37. Ben-Yehoyada M, Ben-Dor I, Shaul Y. c-Abl tyrosine kinase selectively regulates p73 nuclear matrix association. J Biol Chem 2003; 278: 34475-34482.
38. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848.
39. Lau LM, Nugent JK, Zhao X, Irwin MS. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 2008; 27: 997-1003.
40. Kravchenko JE, Ilyinskaya GV, Komarov PG, Agapova LS, Kochetkov DV, Strom E et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci USA 2008; 105: 6302-6307.
41. Carbone A, Cilia AM, Gloghini A, Capello D, Fassone L, Perin T et al. Characterization of a novel HHV-8-positive cell line reveals implications for the pathogenesis and cell cycle control of primary effusion lymphoma. Leukemia 2000; 14: 1301-1309.
42. D'Amours D, Sallmann FR, Dixit VM, Poirier GG. Gain-of-function of poly(ADPribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis. J Cell Sci 2001; 114: 3771-3778.
43. Wong LY, Matchett GA, Wilson AC. Transcriptional activation by the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen is facilitated by an N-terminal chromatin-binding motif. J Virol 2004; 78: 10074-10085.
44. Gwack Y, Hwang S, Byun H, Lim C, Kim JW, Choi EJ et al. Kaposi's sarcomaassociated herpesvirus open reading frame 50 represses p53-induced transcriptional activity and apoptosis. J Virol 2001; 75: 6245-6248.
45. Seo T, Park J, Lee D, Hwang SG, Choe J. Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus binds to p53 and represses p53-dependent transcription and apoptosis. J Virol 2001; 75: 6193-6198.
46. Rivas C, Thlick AE, Parravicini C, Moore PS, Chang Y. Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol 2001; 75: 429-438.
47. Park J, Seo T, Hwang S, Lee D, Gwack Y, Choe J. The K-bZIP protein from Kaposi's sarcoma-associated herpesvirus interacts with p53 and represses its transcriptional activity. J Virol 2000; 74: 11977-11982.
48. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 2008; 22: 2677-2691.
49. Rosenbluth JM, Pietenpol JA. The jury is in: p73 is a tumor suppressor after all. Genes Dev 2008; 22: 2591-2595.
50. Toh WH, Nam SY, Sabapathy K. An essential role for p73 in regulating mitotic cell death. Cell Death Differ 2010; 17: 787-800.
51. Busuttil V, Droin N, McCormick L, Bernassola F, Candi E, Melino G et al. NF-kappaB inhibits T-cell activation-induced, p73-dependent cell death by induction of MDM2. Proc Natl Acad Sci USA 2010; 107: 18061-18066.
52. Amin AR, Paul RK, Thakur VS, Agarwal ML. A novel role for p73 in the regulation of Akt-Foxo1a-Bim signaling and apoptosis induced by the plant lectin, Concanavalin A. Cancer Res 2007; 67: 5617-5621.
53. Sarek G, Ma L, Enbäck J, Järviluoma A, Moreau P, Haas J et al. Kaposi's sarcoma herpesvirus lytic replication compromises apoptotic response to p53 reactivation in virus-induced lymphomas. Oncogene 2013; 32: 1091-1098.
54. Viejo-Borbolla A, Kati E, Sheldon JA, Nathan K, Mattsson K, Szekely L et al. A domain in the C-terminal region of latency-associated nuclear antigen 1 of Kaposi's sarcoma-associated Herpesvirus affects transcriptional activation and binding to nuclear heterochromatin. J Virol 2003; 77: 7093-7100.
55. Platt GM, Simpson GR, Mittnacht S, Schulz TF. Latent nuclear antigen of Kaposi's sarcoma-associated herpesvirus interacts with RING3, a homolog of the Drosophila female sterile homeotic (fsh) gene. J Virol 1999; 73: 9789-9795.
56. Viejo-Borbolla A, Ottinger M, Bruning E, Burger A, Konig R, Kati E et al. Brd2/RING3 interacts with a chromatin-binding domain in the Kaposi's Sarcoma-associated herpesvirus latency-associated nuclear antigen 1 (LANA-1) that is required for multiple functions of LANA-1. J Virol 2005; 79: 13618-13629.